FindTrial
Sign In

Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer

Fluorine-18-α-Methyltyrosine Positron Emission Tomography to Measure Therapy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00826033
Enrollment
Unknown
Registered
2009-01-21
Start date
Unknown
Completion date
Unknown
Last updated
2009-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Keywords

Fluorine-18-α-methyltyrosine, Positron emission tomography, Lung cancer, chemotherapy, monitoring

Brief summary

L-\[3-18F\]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for positron emission tomography (PET). The investigators evaluated the value of 18F-FMT PET for the assessment of therapy response in patients with lung cancer as compared with that of 2-\[18F\]-fluoro-2-deoxy-D-glucose (18F-FDG) PET. The patients with lung cancer underwent PET studies with 18F-FDG and 18F-FMT before and after radio-/chemotherapy. The investigators used the ratio of the SUVmax of the mediastinal (N2) lymph node to the SUVmax of the primary tumor (N/P ratio ). All patients were divided into two groups of N/P ratio\<1 and N/P ratio≥1, and the survival time was estimated by Kaplan-Meier method.

Interventions

None listed

Sponsors

J~pharma
CollaboratorINDUSTRY
Gunma University
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* primary lung cancer All patients received first-line chemotherapy

Exclusion criteria

* Patients with diabetus mellitus

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026